For decades, observations have been made between cancer rates in health care workers with exposure to certain antineoplastics. Published in 2016, USP chapter <800> was introduced to help mitigate risks for patients, the environment, and healthcare personnel. As the years have passed, our understanding of these risks has broadened. With that enhanced knowledge comes new processes and recommendations. This session seeks to examine the progression of USP <800> since its introduction and outline appropriate procedures, education, and monitoring for hazardous drugs included in this chapter.
